Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.
Stocks · News reference
Canaccord Genuity Initiates Coverage On BillionToOne with Buy Rating, Announces Price Target of $120
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million
David Tsao, co-founder and CTO of BillionToOne, sold 10,000 shares for $1 million on August 25, 2026, through a pre-planned Rule 10b5-1 trading arrangement. The sale occurred after the stock declined from a 52-week high of $150.44, but Tsao retains 580,000 stock options, maintaining significant equity alignment with the company. Despite the recent share price drop following Q2 earnings, BillionToOne reported strong 64% year-over-year revenue growth.
Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'
Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.